<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-FENTANYL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FENTANYL" rxcui="4337">
<ATC code="N01AH01" />
<ATC code="N01AH51" />
<ATC code="N02AB03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the anticonvulsant

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose another opioid.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-FENTANYL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FENTANYL" rxcui="4337">
<ATC code="N01AH01" />
<ATC code="N01AH51" />
<ATC code="N02AB03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the opioid analgesic&#39;s effect of respiratory depression due to slight decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is treatment with a strong inhibitor of CYP3A4.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-FENTANYL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FENTANYL" rxcui="4337">
<ATC code="N01AH01" />
<ATC code="N01AH51" />
<ATC code="N02AB03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
<ATC code="J04AM02" />
<ATC code="J04AM05" />
<ATC code="J04AM06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose another opioid.</COMMENT>
</INTERACTION>
</INTERACTIONS>
